Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
EBITDA Margin
-280.10%
TTM · Period ending:
LCTX EBITDA Margin
Latest reported-280.10%period ending
Latest reported-280.10%period ending
LCTX TTM EBITDA Margin (-333.33% → -280.10%)
TTM ebitda margin
High-resolution chart · PNG
LCTX ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -3,764.7971% | |
| -5,375.3387% | |
| -9,528.6868% | |
| -14,507.7547% | |
| -4,781.1396% | |
| -857.1014% | |
| -506.3482% | |
| -458.3333% | |
| -253.3333% | |
| -390% | |
| -363.6364% | |
| -354.5455% | |
| -628.5714% | |
| -528.5714% | |
| -1,166.6667% | |
| -1,000% | |
| -1,300% | |
| -1,100% | |
| -833.3333% | |
| -766.6667% | |
| -333.3333% | |
| -533.3333% | |
| -766.6667% | |
| -766.6667% | |
| -700% | |
| -600% | |
| -500% | |
| -466.6667% | |
| -400% | |
| -400% | |
| -400% | |
| -366.6667% | |
| -366.6667% | |
| -333.3333% |